| Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 … K Choopanya, M Martin, P Suntharasamai, U Sangkum, PA Mock, ... The Lancet 381 (9883), 2083-2090, 2013 | 1639 | 2013 |
| Tenofovir-based preexposure prophylaxis for HIV infection among African women JM Marrazzo, G Ramjee, BA Richardson, K Gomez, N Mgodi, G Nair, ... New England Journal of Medicine 372 (6), 509-518, 2015 | 1469 | 2015 |
| Use of a vaginal ring containing dapivirine for HIV-1 prevention in women JM Baeten, T Palanee-Phillips, ER Brown, K Schwartz, LE Soto-Torres, ... New England Journal of Medicine 375 (22), 2121-2132, 2016 | 853 | 2016 |
| Cabotegravir for HIV prevention in cisgender men and transgender women RJ Landovitz, D Donnell, ME Clement, B Hanscom, L Cottle, L Coelho, ... New England Journal of Medicine 385 (7), 595-608, 2021 | 474 | 2021 |
| Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial S Delany-Moretlwe, JP Hughes, P Bock, SG Ouma, P Hunidzarira, ... The Lancet 399 (10337), 1779-1789, 2022 | 251 | 2022 |
| Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1–serodiscordant couples: a prospective implementation study in Kenya and Uganda JM Baeten, R Heffron, L Kidoguchi, NR Mugo, E Katabira, EA Bukusi, ... PLoS medicine 13 (8), e1002099, 2016 | 213 | 2016 |
| Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis M Gunawardana, M Remedios-Chan, CS Miller, R Fanter, F Yang, ... Antimicrobial agents and chemotherapy 59 (7), 3913-3919, 2015 | 196 | 2015 |
| Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066) CW Hendrix, A Andrade, NN Bumpus, AD Kashuba, MA Marzinke, ... AIDS research and human retroviruses 32 (1), 32-43, 2016 | 172 | 2016 |
| Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial RJ Landovitz, S Li, B Grinsztejn, H Dawood, AY Liu, M Magnus, ... PLoS medicine 15 (11), e1002690, 2018 | 163 | 2018 |
| Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single-or dual-agent preexposure prophylaxis DA Lehman, JM Baeten, CO McCoy, JF Weis, D Peterson, G Mbara, ... The Journal of infectious diseases 211 (8), 1211-1218, 2015 | 143 | 2015 |
| Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind … JM Baeten, D Donnell, NR Mugo, P Ndase, KK Thomas, JD Campbell, ... The Lancet infectious diseases 14 (11), 1055-1064, 2014 | 136 | 2014 |
| Phase 1 safety, pharmacokinetics, and pharmacodynamics of dapivirine and maraviroc vaginal rings: a double-blind randomized trial BA Chen, L Panther, MA Marzinke, CW Hendrix, CJ Hoesley, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 70 (3), 242-249, 2015 | 133 | 2015 |
| Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial RJ Landovitz, S Li, JJ Eron, B Grinsztejn, H Dawood, AY Liu, M Magnus, ... The lancet HIV 7 (7), e472-e481, 2020 | 125 | 2020 |
| Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial LG Bekker, S Roux, E Sebastien, N Yola, KR Amico, JP Hughes, ... The lancet HIV 5 (2), e68-e78, 2018 | 115 | 2018 |
| Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa R Heffron, K Ngure, J Odoyo, N Bulya, E Tindimwebwa, T Hong, ... Gates open research 1, 2017 | 100 | 2017 |
| Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial S Delany-Moretlwe, C Lombard, D Baron, LG Bekker, B Nkala, K Ahmed, ... The Lancet infectious diseases 18 (11), 1241-1250, 2018 | 96 | 2018 |
| Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption KK Mugwanya, CW Hendrix, NR Mugo, M Marzinke, ET Katabira, K Ngure, ... PLoS medicine 13 (9), e1002132, 2016 | 96 | 2016 |
| A phase 1 trial to assess the safety, acceptability, pharmacokinetics, and pharmacodynamics of a novel dapivirine vaginal film KE Bunge, CS Dezzutti, LC Rohan, CW Hendrix, MA Marzinke, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 71 (5), 498-505, 2016 | 89 | 2016 |
| Optimizing pre-exposure antiretroviral prophylaxis adherence in men who have sex with men: Results of a pilot randomized controlled trial of “Life-Steps for PrEP” KH Mayer, SA Safren, SA Elsesser, C Psaros, JP Tinsley, M Marzinke, ... AIDS and Behavior 21, 1350-1360, 2017 | 87 | 2017 |
| Renal function of participants in the Bangkok tenofovir study—Thailand, 2005–2012 M Martin, S Vanichseni, P Suntharasamai, U Sangkum, PA Mock, ... Clinical infectious diseases 59 (5), 716-724, 2014 | 87 | 2014 |
